Dexamethasone a miracle ‘breakthrough’ for seriously ill COVID-19 patients

Dexamethasone is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin, and eye conditions, breathing problems, certain bowel disorders, and certain cancers. It is also used as a test for an adrenal gland disorder [i]

One way that it works is to decrease inflammation in the body. It has been used for Cancer patients. Dexamethasone reduced death rates by around a third among the most severely ill COVID-19 patients that have admitted to hospital. The trail of this drug is  only given to those who have COVID-19 and are on ventilators or are on oxygen.

Full details of the trial have not yet been published. Germany’s Fresenius SE (FREG.DE) is the largest supplier of this drug.

Dexamethasone was first made in 1957 and was approved for medical use in 1961.[5][6] It is on the World Health Organization’s List of Essential Medicines. Source:[ii]

On 16 June 2020, the Oxford University RECOVERY Trial (Randomized Evaluation of COVid-19 Therapy) in the United Kingdom, announced preliminary results that low-dose dexamethasone treatment (6 mg per day either through oral administration or by intravenous injection) can reduce the death rate by approximately one-third in COVID-19 patients on ventilators and by one-fifth in COVID-19 patients on oxygen. No benefits to patients not requiring respiratory support was observed. As of 16 June, the full details of this research have not yet been published. Source:[iii]

Skeletal formula of dexamethasone

 

 

[i] https://www.webmd.com/drugs/2/drug-1027-5021/dexamethasone-oral/dexamethasone-oral/details

[ii] https://en.wikipedia.org/wiki/Dexamethasone

[iii] https://en.wikipedia.org/wiki/Dexamethasone

Image source: https://en.wikipedia.org/wiki/Dexamethasone


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>